Gautam Sarma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gautam Sarma has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Jyotiman Nath
Department of Radiation Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India
6 shared publications - Partha Pratim Medhi
Department of Radiation Oncology, All India Institute of Medical Sciences Guwahati, Changsari, Assam, India
4 shared publications - Apurba Kumar Kalita
Radiation Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, IND
3 shared publications Jyotiman Nath
Department of Radiation Oncology, Dr. B Borooah Cancer Institute, Guwahati, Assam, India
3 shared publicationsApurba Kumar Kalita
Department of Radiation Oncology, Dr B Borooah Cancer Institute, Guwahati, India
2 shared publicationsMouchumee Bhattacharyya
Department of Radiation Oncology, Dr B Borooah Cancer Institute, Guwahati, India
2 shared publications
Latest Publications
- Open Access
- 18 February 2025
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 32 (1) , 22-35
Stereotactic Ablative Radiation Therapy for Metastatic Renal Cell Carcinoma – A Review of Evidence
Because of its remarkable precision in providing targeted radiation, recent evidence supports Stereotactic Ablative Radiation Therapy (SABR) as a promising non-invasive treatment approach for metastatic renal cell carcinoma, minimizing harm to adjacent healthy tissues. With regards to its heterogeneous nature with diverse clinical presentations, rapid progression and metastatic potential, Renal Cell Carcinoma (RCC) is known to make therapy more challenging, and also to reduce the survival rates. Even though Immune Checkpoint Inhibitors (ICIs) remain the gold standard for treating metastatic RCC (mRCC), certain patients with one or a few distant metastases seem to have a longer survival period if the metastases are surgically removed. However, complete responses are not always the case, with radiation being increasingly incorporated as a component of multidisciplinary care. Moreover, studies proving the immunogenic qualities of hypofractionated SABR and the safety and potential of combining SABR with immune-based and surgical therapy for mRCC are becoming more prevalent in the literature. SABR helps induce local inflammation with the tumour, promoting T cell activation and antigen presentation. Multiple retrospective and prospective reports have also demonstrated that SABR assigned to the metastatic locations of mRCC, while using ablative dosages, achieves high local control rates with a good toxicity profile, thus disproving earlier theories of RCC radioresistance. This review outlines the key evidence favouring SABR being administered to metastatic tumours, including the results of recent prospective phase 2 trials in patients with oligometastatic, oligoprogressive, and unselected mRCC. The body of data that has been gathered points to SABR as a promising indicator that is being utilized more and more in the multidisciplinary management of mRCC.
- 18 February 2025
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 32 (1) , 22-35
Open AccessStereotactic Ablative Radiation Therapy for Metastatic Renal Cell Carcinoma – A Review of Evidence
Because of its remarkable precision in providing targeted radiation, recent evidence supports Stereotactic Ablative Radiation Therapy (SABR) as a promising non-invasive treatment approach for metastatic renal cell carcinoma, minimizing harm to adjacent healthy tissues. With regards to its heterogeneous nature with diverse clinical presentations, rapid progression and metastatic potential, Renal Cell Carcinoma (RCC) is known to make therapy more challenging, and also to reduce the survival rates. Even though Immune Checkpoint Inhibitors (ICIs) remain the gold standard for treating metastatic RCC (mRCC), certain patients with one or a few distant metastases seem to have a longer survival period if the metastases are surgically removed. However, complete responses are not always the case, with radiation being increasingly incorporated as a component of multidisciplinary care. Moreover, studies proving the immunogenic qualities of hypofractionated SABR and the safety and potential of combining SABR with immune-based and surgical therapy for mRCC are becoming more prevalent in the literature. SABR helps induce local inflammation with the tumour, promoting T cell activation and antigen presentation. Multiple retrospective and prospective reports have also demonstrated that SABR assigned to the metastatic locations of mRCC, while using ablative dosages, achieves high local control rates with a good toxicity profile, thus disproving earlier theories of RCC radioresistance. This review outlines the key evidence favouring SABR being administered to metastatic tumours, including the results of recent prospective phase 2 trials in patients with oligometastatic, oligoprogressive, and unselected mRCC. The body of data that has been gathered points to SABR as a promising indicator that is being utilized more and more in the multidisciplinary management of mRCC.
- 13 January 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 15 (2) , 241-249
Real-World Experience of Patient’s Compliance and Clinical Outcomes for Trimodality Treatment for Esophageal Cancer: a Study from a Cancer Center in North-East India
Preoperative chemoradiotherapy is a standard treatment for patients with locally advanced, resectable esophageal cancer. The treatment completion rates impact the survival outcomes (Eyck et al J Clin Oncol 39(18):1995–2004, 2021). Thus, we aimed to estimate the effect of neoadjuvant chemoradiotherapy (NACRT) in terms of treatment completion rates and survival in this subset of patients and bring out the clinical outcomes in that context. This was a retrospective study done at a tertiary cancer center in North-East India. The study period was from 1 January 2018 to 31 December 2021. We included patients diagnosed with locally advanced and resectable esophageal cancer (cT2-3NanyM0) involving the middle and/or lower thoracic esophagus and who were planned for trimodality treatment in the Joint Tumor Board. Out of the 82 patients who were planned for trimodality treatment, all were squamous cell carcinomas. We found that 54.9% of patients completed the entire trimodality treatment. The median age was 56 years (range 34 to 73 years). The male to female ratio was 59:23. Adverse events, of any grade, were seen in 76% of patients who received NACRT. Fatigue (66%) was the most common toxicity. The common hematologic toxicities were neutropenia and anemia (7.3% each). A total of 45 patients (54.9%) were able to complete all the three modalities of treatment. Transthoracic esophagectomy was the preferred approach (84.4%). The site of anastomosis was in the neck of all the patients. Anastomotic leak was seen in 17.7% of patients. Postoperative pulmonary and cardiac complications occurred in 31.1% and 8.9% of patients respectively. The 30-day mortality was 6.7% (three deaths). A pathological complete response was seen in 35.6% among patients who underwent an esophagectomy. R0 resection was achieved in 93.3% of patients. The median overall survival and disease-free survival were 19 months and 17 months respectively. The completion rate of trimodality treatment in the real-world scenario was found to be low in our study, the reasons for which need to be identified and effectively resolved. Oncological outcomes were similar to the published literature.
- 13 January 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 15 (2) , 241-249
Real-World Experience of Patient’s Compliance and Clinical Outcomes for Trimodality Treatment for Esophageal Cancer: a Study from a Cancer Center in North-East India
Preoperative chemoradiotherapy is a standard treatment for patients with locally advanced, resectable esophageal cancer. The treatment completion rates impact the survival outcomes (Eyck et al J Clin Oncol 39(18):1995–2004, 2021). Thus, we aimed to estimate the effect of neoadjuvant chemoradiotherapy (NACRT) in terms of treatment completion rates and survival in this subset of patients and bring out the clinical outcomes in that context. This was a retrospective study done at a tertiary cancer center in North-East India. The study period was from 1 January 2018 to 31 December 2021. We included patients diagnosed with locally advanced and resectable esophageal cancer (cT2-3NanyM0) involving the middle and/or lower thoracic esophagus and who were planned for trimodality treatment in the Joint Tumor Board. Out of the 82 patients who were planned for trimodality treatment, all were squamous cell carcinomas. We found that 54.9% of patients completed the entire trimodality treatment. The median age was 56 years (range 34 to 73 years). The male to female ratio was 59:23. Adverse events, of any grade, were seen in 76% of patients who received NACRT. Fatigue (66%) was the most common toxicity. The common hematologic toxicities were neutropenia and anemia (7.3% each). A total of 45 patients (54.9%) were able to complete all the three modalities of treatment. Transthoracic esophagectomy was the preferred approach (84.4%). The site of anastomosis was in the neck of all the patients. Anastomotic leak was seen in 17.7% of patients. Postoperative pulmonary and cardiac complications occurred in 31.1% and 8.9% of patients respectively. The 30-day mortality was 6.7% (three deaths). A pathological complete response was seen in 35.6% among patients who underwent an esophagectomy. R0 resection was achieved in 93.3% of patients. The median overall survival and disease-free survival were 19 months and 17 months respectively. The completion rate of trimodality treatment in the real-world scenario was found to be low in our study, the reasons for which need to be identified and effectively resolved. Oncological outcomes were similar to the published literature.
- Open Access
- 1 October 2023
- Published by Medknow in Journal of Medical Physics
- Vol. 48 (4) , 398-401
Split X-jaw Planning Technique of Volumetric Modulated Arc Radiotherapy
This brief communication article examines the constraints posed by the Varian linear accelerator machine’s volumetric-modulated arc therapy (VMAT) due to the maximum extent of the multileaf collimator (MLC) in the x-jaw direction. The MLC leaves within this machine are capable of extending up to 15 cm in the x-jaw direction. However, when VMAT is employed with excessive extension, modulation level decreases, leading to compromised target dose distribution, and the protection of critical organs. The existing VMAT techniques involve open and limited x-jaw approaches, but these methods present avenues for enhancement. One innovative approach is the split x-jaw planning technique, which involves segmenting the open field into two distinct fields with some overlap. This strategy yields four treatment arcs that comprehensively cover the planning target volume (PTV). Enhancing modulation and conformity can be achieved by restricting each field’s size to 15 cm. Consequently, this technique demonstrates improved target dose distributions, heightened plan conformity, and more effective sparing of organs at risk compared to the limited and open methodologies. Initial dosimetric studies suggest that the split X-jaw technique holds promise as a superior planning solution for larger PTVs that exceed the MLC’s maximum x-jaw extent.
- 1 October 2023
- Published by Medknow in Journal of Medical Physics
- Vol. 48 (4) , 398-401
Open AccessSplit X-jaw Planning Technique of Volumetric Modulated Arc Radiotherapy
This brief communication article examines the constraints posed by the Varian linear accelerator machine’s volumetric-modulated arc therapy (VMAT) due to the maximum extent of the multileaf collimator (MLC) in the x-jaw direction. The MLC leaves within this machine are capable of extending up to 15 cm in the x-jaw direction. However, when VMAT is employed with excessive extension, modulation level decreases, leading to compromised target dose distribution, and the protection of critical organs. The existing VMAT techniques involve open and limited x-jaw approaches, but these methods present avenues for enhancement. One innovative approach is the split x-jaw planning technique, which involves segmenting the open field into two distinct fields with some overlap. This strategy yields four treatment arcs that comprehensively cover the planning target volume (PTV). Enhancing modulation and conformity can be achieved by restricting each field’s size to 15 cm. Consequently, this technique demonstrates improved target dose distributions, heightened plan conformity, and more effective sparing of organs at risk compared to the limited and open methodologies. Initial dosimetric studies suggest that the split X-jaw technique holds promise as a superior planning solution for larger PTVs that exceed the MLC’s maximum x-jaw extent.
- 31 August 2023
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 76 (1) , 1425-1429
ChatGPT in Head and Neck Oncology-Opportunities and Challenges
Head and neck oncology represents a complex and challenging field, encompassing the diagnosis, treatment and management of various malignancies affecting the intricate anatomical structures of the head and neck region. With advancements in artificial intelligence (AI), chatbot applications have emerged as a promising tool to revolutionize the field of Head and Neck oncology. ChatGPT is a cutting-edge language model developed by OpenAI that can help the oncologist in the clinic in scheduling appointments, establishing a clinical diagnosis, making a treatment plan and follow-up. ChatGPT also plays an essential role in telemedicine consultations, medical documentation, scientific writing and research. ChatGPT carries its inherent drawbacks too. ChatGPT raises significant ethical concerns related to authorship, accountability, transparency, bias, and the potential for misinformation. ChatGPT’s training data is limited to September 2021; thus, regular updates are required to keep pace with the rapidly evolving medical research and advancements. Therefore, a judicial approach to using ChatGPT is of utmost importance. Head and Neck Oncologists can reap the maximum benefit of this technology in terms of patient care, education and research to improve clinical outcomes.
- 31 August 2023
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 76 (1) , 1425-1429
ChatGPT in Head and Neck Oncology-Opportunities and Challenges
Head and neck oncology represents a complex and challenging field, encompassing the diagnosis, treatment and management of various malignancies affecting the intricate anatomical structures of the head and neck region. With advancements in artificial intelligence (AI), chatbot applications have emerged as a promising tool to revolutionize the field of Head and Neck oncology. ChatGPT is a cutting-edge language model developed by OpenAI that can help the oncologist in the clinic in scheduling appointments, establishing a clinical diagnosis, making a treatment plan and follow-up. ChatGPT also plays an essential role in telemedicine consultations, medical documentation, scientific writing and research. ChatGPT carries its inherent drawbacks too. ChatGPT raises significant ethical concerns related to authorship, accountability, transparency, bias, and the potential for misinformation. ChatGPT’s training data is limited to September 2021; thus, regular updates are required to keep pace with the rapidly evolving medical research and advancements. Therefore, a judicial approach to using ChatGPT is of utmost importance. Head and Neck Oncologists can reap the maximum benefit of this technology in terms of patient care, education and research to improve clinical outcomes.
- 4 July 2023
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 75 (4) , 3519-3529
Definitive Radiotherapy in Locally Advanced Head and Neck Squamous Cell Cancer with Clinical Extranodal Extension
Purpose The extranodal extension (ENE) in head and neck squamous cell carcinoma (HNSCC) is a potential poor prognostic factor. Clinical ENE (cENE) was incorporated in the HNSCC staging system in the 8th edition of AJCC. There is not much evidence to support the treatment of HNSCC with cN3b with radiotherapy in radical intent. This study aims to assess the treatment outcome in patients of HNSCC with cN3b disease treated with definitive radiotherapy. Method Forty-five HNSCC patients with cN3b disease treated with definitive radiotherapy with or without concurrent chemotherapy between January 2018 to December 2018 were retrospectively evaluated. Results The median age of the study patients was 60 years (40–75years). Only 35 patients (77.8%) could complete the prescribed course of treatment, and the leading common cause of non-completion was treatment-related toxicities. After a median follow-up period of 9.3 months (range 2–33), the median OS and PFS were 22.6 months and 7.2 months, respectively. Fourteen patients (31.1%) in our study developed grade III/IV mucositis, and 11 (24.4%) developed severe grade III/IV dermatitis. The locoregional failure constituted 24 patients (53.3%). Conclusion The treatment outcome of HNSCC with cN3b disease is inferior. A personalized and subjective approach should be undertaken before choosing radiotherapy with a radical intent in this group of patients.
- 4 July 2023
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 75 (4) , 3519-3529
Definitive Radiotherapy in Locally Advanced Head and Neck Squamous Cell Cancer with Clinical Extranodal Extension
Purpose The extranodal extension (ENE) in head and neck squamous cell carcinoma (HNSCC) is a potential poor prognostic factor. Clinical ENE (cENE) was incorporated in the HNSCC staging system in the 8th edition of AJCC. There is not much evidence to support the treatment of HNSCC with cN3b with radiotherapy in radical intent. This study aims to assess the treatment outcome in patients of HNSCC with cN3b disease treated with definitive radiotherapy. Method Forty-five HNSCC patients with cN3b disease treated with definitive radiotherapy with or without concurrent chemotherapy between January 2018 to December 2018 were retrospectively evaluated. Results The median age of the study patients was 60 years (40–75years). Only 35 patients (77.8%) could complete the prescribed course of treatment, and the leading common cause of non-completion was treatment-related toxicities. After a median follow-up period of 9.3 months (range 2–33), the median OS and PFS were 22.6 months and 7.2 months, respectively. Fourteen patients (31.1%) in our study developed grade III/IV mucositis, and 11 (24.4%) developed severe grade III/IV dermatitis. The locoregional failure constituted 24 patients (53.3%). Conclusion The treatment outcome of HNSCC with cN3b disease is inferior. A personalized and subjective approach should be undertaken before choosing radiotherapy with a radical intent in this group of patients.
- 21 April 2023
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 14 (3) , 699-706
Intensity Modulated Radiotherapy in Head and Neck Cancer: Initial Experience of the First Treated Cases from North-East India
Head and neck cancer incidence is relatively higher in north-eastern states than in other parts of India. Intensity-modulated radiotherapy (IMRT) was first introduced in our institute in 2012 to cater the entire north-east. This study attempts to assess the treatment outcomes and prognostic factors of head and neck cancer patients who had been treated with definitive radiotherapy in our institute from 2012 to 2016 using IMRT. This is a single institutional retrospective study. Thirty-six patients of head and neck cancer other than nasopharynx primary treated with definitive radiotherapy using IMRT between 2012 to 2016 were evaluated. The survival was analyzed using the Kaplan–Meir method, and various clinicopathologic factors were compared. The median age of the study patients was 58 years (range 24–79 years). The majority of the patients (69.4%) were below the age of 50 years. Thirty-two patients (88.9%) were male, and only four (11.1%) were females. After a median follow-up time of 40 months (7–84 months), the 5-year overall survival (OS) was 42.1%. The stage at presentation and radiotherapy treatment time were found to be significant prognostic factors of the outcome. The treatment-related toxicities were within acceptable limits. This retrospective study has reported the outcome and treatment-related toxicities of initially treated HNC patients with IMRT from northeast India.
- 21 April 2023
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 14 (3) , 699-706
Intensity Modulated Radiotherapy in Head and Neck Cancer: Initial Experience of the First Treated Cases from North-East India
Head and neck cancer incidence is relatively higher in north-eastern states than in other parts of India. Intensity-modulated radiotherapy (IMRT) was first introduced in our institute in 2012 to cater the entire north-east. This study attempts to assess the treatment outcomes and prognostic factors of head and neck cancer patients who had been treated with definitive radiotherapy in our institute from 2012 to 2016 using IMRT. This is a single institutional retrospective study. Thirty-six patients of head and neck cancer other than nasopharynx primary treated with definitive radiotherapy using IMRT between 2012 to 2016 were evaluated. The survival was analyzed using the Kaplan–Meir method, and various clinicopathologic factors were compared. The median age of the study patients was 58 years (range 24–79 years). The majority of the patients (69.4%) were below the age of 50 years. Thirty-two patients (88.9%) were male, and only four (11.1%) were females. After a median follow-up time of 40 months (7–84 months), the 5-year overall survival (OS) was 42.1%. The stage at presentation and radiotherapy treatment time were found to be significant prognostic factors of the outcome. The treatment-related toxicities were within acceptable limits. This retrospective study has reported the outcome and treatment-related toxicities of initially treated HNC patients with IMRT from northeast India.
- 1 January 2023
- Published by Medknow in Journal of Head & Neck Physicians and Surgeons
- Vol. 11 (1) , 20-25
Locoregional Radiotherapy in Metastatic Nasopharyngeal Cancer – Review Article of Recent Trials
Nasopharyngeal cancer (NPC) has a high prevalence in Southeast Asian regions and up to 80% of patients present with locally advanced disease. Almost 10% present with distant metastases, associated with unfavorable outcomes and poor prognosis. With the advent of newer radiotherapy techniques and systemic therapy, a good cure can be achieved in early and locally advanced diseases. However, the mainstay of treatment in metastatic NPC remains to be only palliative chemotherapy. Recently various studies have been conducted to validate the role of local radiotherapy in the locoregional site in a metastatic setting along with systemic therapy. Hence, here, we present a review of the literature supporting the addition of radiotherapy to the locoregional site in metastatic NPC.
- 1 January 2023
- Published by Medknow in Journal of Head & Neck Physicians and Surgeons
- Vol. 11 (1) , 20-25
Locoregional Radiotherapy in Metastatic Nasopharyngeal Cancer – Review Article of Recent Trials
Nasopharyngeal cancer (NPC) has a high prevalence in Southeast Asian regions and up to 80% of patients present with locally advanced disease. Almost 10% present with distant metastases, associated with unfavorable outcomes and poor prognosis. With the advent of newer radiotherapy techniques and systemic therapy, a good cure can be achieved in early and locally advanced diseases. However, the mainstay of treatment in metastatic NPC remains to be only palliative chemotherapy. Recently various studies have been conducted to validate the role of local radiotherapy in the locoregional site in a metastatic setting along with systemic therapy. Hence, here, we present a review of the literature supporting the addition of radiotherapy to the locoregional site in metastatic NPC.
- Open Access
- 1 January 2023
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 11 (3) , 183-190
Factors Associated With Neurocognitive Impairment Following Chemoradiotherapy in Patients With High-Grade Glioma: Results of a Prospective Trial
Sharma P, et al. Brain Tumor Res Treat. 2023 Jul;11(3):183-190. https://doi.org/10.14791/btrt.2023.0004
- 1 January 2023
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 11 (3) , 183-190
Open AccessFactors Associated With Neurocognitive Impairment Following Chemoradiotherapy in Patients With High-Grade Glioma: Results of a Prospective Trial
Sharma P, et al. Brain Tumor Res Treat. 2023 Jul;11(3):183-190. https://doi.org/10.14791/btrt.2023.0004
- 13 May 2022
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 22, 1-6
Impact of split X-jaw technique on target volume coverage and organ at risk sparing in prostate cancer: a comparative dosimetric study
Introduction:The Varian Trilogy linear accelerator’s multi-leaf collimator moves on a carriage with a maximum leaf span of 15 cm. The traditional open and limited X-jaw technique of volumetric-modulated arc radiotherapy (VMAT) yields a relatively compromised dose distribution within the planning target volume (PTV) region. This study aimed to determine whether the split X-jaw planning technique for VMAT improves plan quality regarding target dose coverage and organs at risk (OAR) sparing for PTVs that require a field size of more than 15 cm in the X-jaw direction in prostate cancer patients.Method:Computed tomography data sets from 15 patients with prostate cancer were enrolled in the study. Only the PTVs requiring a field size larger than 18 cm in the X-jaw position were considered, and a dose of 4500 cGy in 25 fractions was prescribed. For each case, three separate treatment plans were generated: open, limited and split X-jaw planning techniques with similar planning objectivesResults:The split X-jaw technique resulted in statistically significant superior coverage of PTV when compared with the open (P < 0·0001) and limited methods (P < 0·001). The split technique delivered a lower dose to the OARs, although statistical significance could not be achieved. D2% (cGy) was lowest for the PTV in the split technique (4684·8 ± 18·16) and highest for the open technique (4710 ± 18·75), P < 0·001.Conclusion:The x-split jaw technique can replace the traditional open X-jaw practice of VMAT for PTVs requiring an X-jaw width of more than 15 cm in the Varian linear accelerator.
- 13 May 2022
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 22, 1-6
Impact of split X-jaw technique on target volume coverage and organ at risk sparing in prostate cancer: a comparative dosimetric study
Introduction:The Varian Trilogy linear accelerator’s multi-leaf collimator moves on a carriage with a maximum leaf span of 15 cm. The traditional open and limited X-jaw technique of volumetric-modulated arc radiotherapy (VMAT) yields a relatively compromised dose distribution within the planning target volume (PTV) region. This study aimed to determine whether the split X-jaw planning technique for VMAT improves plan quality regarding target dose coverage and organs at risk (OAR) sparing for PTVs that require a field size of more than 15 cm in the X-jaw direction in prostate cancer patients.Method:Computed tomography data sets from 15 patients with prostate cancer were enrolled in the study. Only the PTVs requiring a field size larger than 18 cm in the X-jaw position were considered, and a dose of 4500 cGy in 25 fractions was prescribed. For each case, three separate treatment plans were generated: open, limited and split X-jaw planning techniques with similar planning objectivesResults:The split X-jaw technique resulted in statistically significant superior coverage of PTV when compared with the open (P < 0·0001) and limited methods (P < 0·001). The split technique delivered a lower dose to the OARs, although statistical significance could not be achieved. D2% (cGy) was lowest for the PTV in the split technique (4684·8 ± 18·16) and highest for the open technique (4710 ± 18·75), P < 0·001.Conclusion:The x-split jaw technique can replace the traditional open X-jaw practice of VMAT for PTVs requiring an X-jaw width of more than 15 cm in the Varian linear accelerator.
- Open Access
- 25 October 2021
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 74 (S3) , 6219-6224
Dental Care in Head and Neck Cancer Patients Undergoing Radiotherapy
External beam radiotherapy is an integral part of the management of head and neck cancer. Radiotherapy for head and neck cancer lead to many treatment-related toxicities, including a wide range of dental morbidities. These complications depend on the various patient and treatment-related factors. Patients with poor oral hygiene, pre-existing periodontal disease, and the conventional mode of radiotherapy delivery are major factors leading to acute and severe late dental problems. Most of the complications are preventable with proper oral and dental care before, during and after radiotherapy. Pre radiotherapy dental evaluation to diagnose patients with potential risk and timely intervention can reduce long-term morbidities like carries, osteoradionecrosis, etc., thereby improving patients’ quality of life. This article highlights the various aspects of dental care and management in head neck cancer patients before, during and after radiation therapy.
- 25 October 2021
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 74 (S3) , 6219-6224
Open AccessDental Care in Head and Neck Cancer Patients Undergoing Radiotherapy
External beam radiotherapy is an integral part of the management of head and neck cancer. Radiotherapy for head and neck cancer lead to many treatment-related toxicities, including a wide range of dental morbidities. These complications depend on the various patient and treatment-related factors. Patients with poor oral hygiene, pre-existing periodontal disease, and the conventional mode of radiotherapy delivery are major factors leading to acute and severe late dental problems. Most of the complications are preventable with proper oral and dental care before, during and after radiotherapy. Pre radiotherapy dental evaluation to diagnose patients with potential risk and timely intervention can reduce long-term morbidities like carries, osteoradionecrosis, etc., thereby improving patients’ quality of life. This article highlights the various aspects of dental care and management in head neck cancer patients before, during and after radiation therapy.